Senseonics Holdings, Inc. (NYSEAMERICAN:SENS – Get Rating) shares gapped up prior to trading on Wednesday . The stock had previously closed at $1.27, but opened at $1.33. Senseonics shares last traded at $1.54, with a volume of 68,982 shares changing hands.
Senseonics Price Performance
The firm has a market cap of $940.42 million, a P/E ratio of -2.45 and a beta of 0.61.
Get
Senseonics alerts:
Senseonics (NYSEAMERICAN:SENS – Get Rating) last released its quarterly earnings results on Tuesday, May 10th. The company reported ($0.03) earnings per share (EPS) for the quarter, hitting analysts' consensus estimates of ($0.03). The firm had revenue of $2.48 million for the quarter, compared to analysts' expectations of $2.14 million. Analysts expect that Senseonics Holdings, Inc. will post -0.16 earnings per share for the current year.
Institutional Inflows and Outflows
A number of hedge funds have recently added to or reduced their stakes in the company. National Bank of Canada FI acquired a new stake in Senseonics during the 4th quarter worth approximately $43,000. Allspring Global Investments Holdings LLC acquired a new stake in Senseonics during the 4th quarter worth approximately $547,000. Commonwealth Equity Services LLC lifted its position in Senseonics by 19.7% during the 4th quarter. Commonwealth Equity Services LLC now owns 136,448 shares of the company's stock worth $364,000 after acquiring an additional 22,412 shares during the period. Zurcher Kantonalbank Zurich Cantonalbank lifted its holdings in shares of Senseonics by 114.3% in the 4th quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 44,281 shares of the company's stock valued at $118,000 after buying an additional 23,617 shares during the period. Finally, Argent Advisors Inc. acquired a new stake in shares of Senseonics in the 4th quarter valued at approximately $27,000. Hedge funds and other institutional investors own 26.81% of the company's stock.
About Senseonics
(Get Rating)
Senseonics Holdings, Inc, a medical technology company, develops and commercializes continuous glucose monitoring (CGM) systems for people with diabetes in the United States, Europe, the Middle East, and Africa. The company's products include Eversense and Eversense XL, which are implantable CGM systems to measure glucose levels in people with diabetes through an under-the-skin sensor, a removable and rechargeable smart transmitter, and a convenient app for real-time diabetes monitoring and management for a period of up to six months.
Read More
- Get a free copy of the StockNews.com research report on Senseonics (SENS)
- 3 Hotel Stocks to Consider Checking into After Earnings
- How Does Freeport McMoran Inc Compare to Its Sector Competitors?
- Can FuelCell Energy Surge Higher This Year?
- Is It Time to Take a Ride on Cedar Fair Stock?
- These Are The Top Insider Buying Stocks For July
Receive News & Ratings for Senseonics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Senseonics and related companies with MarketBeat.com's FREE daily email newsletter.
